心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：肺动脉去神经术对药物反应不佳的IPAH患者有效

2013-07-31 coffeecoffee dxy

肺动脉去神经术IPAH功能
关注

压力感受器和交感神经纤维均位于或靠近肺动脉分叉区域。早先研究发现肺动脉（PA）去神经术（PADN）可完全消除肺动脉左叶间闭合引起的肺动脉压升高。但尚无研究证实肺动脉去神经术对特发性肺动脉高压（IPAH）患者的疗效。南京医科大学陈绍良等人对此进行了研究，结果发现，PADN对药物治疗反应不佳的IPAH患者有疗效，结果于7月在线发表于《美国心脏病学杂志》。 研究招募的21名IPAH患者中，有13名接受

压力感受器和交感神经纤维均位于或靠近肺动脉分叉区域。早先研究发现肺动脉（PA）去神经术（PADN）可完全消除肺动脉左叶间闭合引起的肺动脉压升高。但尚无研究证实肺动脉去神经术对特发性肺动脉高压（IPAH）患者的疗效。南京医科大学陈绍良等人对此进行了研究，结果发现，PADN对药物治疗反应不佳的IPAH患者有疗效，结果于7月在线发表于《美国心脏病学杂志》。

研究招募的21名IPAH患者中，有13名接受了PADN术，剩余8名拒绝接受PADN手术的患者分配为对照组。PADN术在主肺动脉分叉以及左、右肺动脉开口处实施，并进行一系列超声心动图、右心导管插入和六分钟步行测试（6MWT）。研究主要终点为随访三个月时肺动脉压力（PAP）、三尖瓣偏移（Tei）指数和六分钟步行测试。

随访三个月后，与对照组相比，接受PADN术的患者平均PAP水平显著降低，六分钟步行测试显著改善，Tei指数也显著提高。

这项研究首次显示，在对药物治疗反应不佳的IPAH患者中，PADN术可改善患者的功能和血流动力学。不过PADN的具体疗效仍有待进一步随机化试验验证。

Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, Stone GW.Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study.J Am Coll Cardiol. 2013 Jul 3. doi:pii: S0735-1097(13)02589-8. 10.1016/j.jacc.2013.05.075. [Epub ahead of print]

PMID:
23850902
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952881, encodeId=0765195288129, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jan 05 16:54:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853239, encodeId=b3a71853239c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 03 10:54:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324832, encodeId=fe171324832ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460186, encodeId=8d5e146018608, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=)]
    2014-01-05 lfcmxl

    #药物反应#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1952881, encodeId=0765195288129, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jan 05 16:54:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853239, encodeId=b3a71853239c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 03 10:54:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324832, encodeId=fe171324832ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460186, encodeId=8d5e146018608, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=)]
    2013-09-03 hbwxf

    #JACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1952881, encodeId=0765195288129, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jan 05 16:54:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853239, encodeId=b3a71853239c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 03 10:54:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324832, encodeId=fe171324832ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460186, encodeId=8d5e146018608, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=)]
    2013-08-02 12498568m50暂无昵称

    #ACC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1952881, encodeId=0765195288129, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sun Jan 05 16:54:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853239, encodeId=b3a71853239c0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 03 10:54:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324832, encodeId=fe171324832ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460186, encodeId=8d5e146018608, content=<a href='/topic/show?id=1519136e641' target=_blank style='color:#2F92EE;'>#PAH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13676, encryptionId=1519136e641, topicName=PAH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87966261195, createdName=hb2010ye, createdTime=Fri Aug 02 06:54:00 CST 2013, time=2013-08-02, status=1, ipAttribution=)]
    2013-08-02 hb2010ye

    #PAH#

    0

相关资讯

JACC：肺动脉去神经术或对药物反应不佳的IPAH有效

由陈绍良等进行的一项研究表明，在药物治疗反应不佳的特发性肺动脉高压（IPAH）患者中，肺动脉去神经术（PADN）可对功能能力和血流动力学指标产生积极影响。论文发表于7月的《美国心脏病学会杂志》（JACC）电子版。 此项研究共纳入21例对药物治疗反应不佳的IPAH患者，其中13例接受PADN治疗，另外8例拒绝PAND治疗的患者被分入对照组。在主肺动脉分叉以及左、右肺动脉开口处实施PADN。主要终点